PHMMF OTC
Pharma Mar, S.A.
1W: +0.0%
1M: +0.0%
3M: +19.0%
YTD: +9.7%
1Y: -7.5%
3Y: +193.2%
5Y: +10.3%
$94.60
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$221M
+26.6% ▲
5Y CAGR: -3.9%
Gross Profit
$209M
+25.4% ▲
5Y CAGR: -4.0%
Operating Income
$40M
+522.5% ▲
5Y CAGR: -23.7%
Net Income
$75M
+186.9% ▲
5Y CAGR: -11.4%
EPS (Diluted)
$4.36
+192.6% ▲
5Y CAGR: -10.3%
EBITDA
$48M
+127.4% ▲
5Y CAGR: -20.9%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $230M | $196M | $158M | $175M | $221M |
| YoY Growth | -14.9% | -14.6% | -19.5% | +10.6% | +26.6% |
| Cost of Revenue | $16M | $14M | $10M | $8M | $12M |
| Gross Profit | $213M | $183M | $149M | $167M | $209M |
| Gross Margin | 92.8% | 93.1% | 93.9% | 95.3% | 94.5% |
| R&D Expenses | $72M | $83M | $99M | $104M | $95M |
| SG&A Expenses | $40M | $43M | $42M | -$3M | $59M |
| Operating Expenses | $121M | $138M | $152M | $160M | $169M |
| Operating Income | $92M | $44M | -$4M | $6M | $40M |
| Operating Margin | 40.2% | 22.4% | -2.4% | 3.7% | 18.2% |
| Interest Expense | $3M | $2M | $2M | $2M | $1M |
| Income Before Tax | $95M | $44M | -$4M | $12M | $60M |
| Tax Expense | $2M | -$6M | -$5M | -$14M | -$15M |
| Net Income | $93M | $49M | $1M | $26M | $75M |
| Net Margin | 40.4% | 25.1% | 0.7% | 14.9% | 33.9% |
| EPS (Diluted) | $5.13 | $2.73 | $0.06 | $1.49 | $4.36 |
| EBITDA | $104M | $52M | $5M | $21M | $48M |
| Shares Outstanding | 18M | 18M | 18M | 18M | 17M |